title: Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma.
abstract: BACKGROUND
  Combination therapies have gained momentum in the disease management strategies of various indications. While it is challenging and more time consuming to develop a combined analytical method, the strategy of simultaneous analysis offers significant advantages in terms of efficiency and cost-effectiveness.
  
  
  RESULTS
  Due to a significant difference in efficacious dose for ceftazidime and avibactam, the calibration ranges validated in this paper were set to 0.05-50 μg/ml for ceftazidime and 0.005-5.0 μg/ml for avibactam. Interday results of ceftazidime were within 8% for accuracy and 9% for precision and within 9% for both accuracy and precision of avibactam.
  
  
  CONCLUSIONS
  A sensitive and selective LC-MS/MS method was developed for the simultaneous quantification of ceftazidime and avibactam in rat plasma.
authors.affiliation: DMPK Oncology iMED, AstraZeneca, Waltham, MA, USA.
authors.forename: Marie-Eve
authors.initials: ME
authors.lastname: Beaudoin
authors.affiliation: DMPK Oncology iMED, AstraZeneca, Waltham, MA, USA.
authors.forename: Eric T
authors.initials: ET
authors.lastname: Gangl
mesh_terms: D053000:Analytic Sample Preparation Methods; D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood*; D053961:Azabicyclo Compounds / Q000097:blood*; D001774:Blood Chemical Analysis / Q000379:methods*; D002138:Calibration; D002442:Ceftazidime / Q000097:blood*; D002853:Chromatography, Liquid; D004355:Drug Stability; D005615:Freezing; D057230:Limit of Detection; D051381:Rats; D053719:Tandem Mass Spectrometry; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; C543519:avibactam; D002442:Ceftazidime
keywords: antibacterial resistance; avibactam; ceftazidime; cephalosporins; combination therapy